Literature DB >> 17574793

Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Alan I Green1, Douglas L Noordsy, Mary F Brunette, Christopher O'Keefe.   

Abstract

Substance use disorder is common in patients with schizophrenia and dramatically worsens their outcome. The typical antipsychotic medications, introduced more than 50 years ago, are effective for the treatment of psychosis but may have only limited efficacy in patients with these co-occurring disorders because patients continue to use substances while taking them. In preliminary studies, however, several of the atypical antipsychotic medications have shown promise for reducing alcohol and drug use in patients with schizophrenia. A neurobiological formulation is discussed, suggesting that the use of substances in patients with schizophrenia may be based on a dysfunction within the dopamine-mediated brain reward circuitry and that clozapine, in particular, may potentially ameliorate this dysfunction and lessen the desire for substance use. Medications for the treatment of alcohol use disorders, such as disulfiram, naltrexone, and acamprosate, as well as other adjunctive medications, may also be useful. Further studies are required to establish a solid evidence base of best practices for the use of medications in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574793      PMCID: PMC2930488          DOI: 10.1016/j.jsat.2007.01.008

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  115 in total

1.  Disulfiram in the treatment of alcoholic patients with schizophrenia.

Authors:  S J Kingsbury; C Salzman
Journal:  Hosp Community Psychiatry       Date:  1990-02

2.  Relationships between symptoms of schizophrenia and substance abuse.

Authors:  M F Brunette; K T Mueser; H Xie; R E Drake
Journal:  J Nerv Ment Dis       Date:  1997-01       Impact factor: 2.254

3.  Liver toxicity encountered in the Veterans Administration trial of disulfiram in alcoholics.

Authors:  F L Iber; K Lee; R Lacoursiere; R Fuller
Journal:  Alcohol Clin Exp Res       Date:  1987-06       Impact factor: 3.455

4.  Drug abuse and mental illness.

Authors:  M P Weller; P C Ang; D T Latimer-Sayer; A Zachary
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

Review 5.  HIV seroprevalence among people with severe mental illness in the United States: a critical review.

Authors:  F Cournos; K McKinnon
Journal:  Clin Psychol Rev       Date:  1997

6.  Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys.

Authors:  J W Swanson; C E Holzer; V K Ganju; R T Jono
Journal:  Hosp Community Psychiatry       Date:  1990-07

7.  Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.

Authors:  K T Mueser; P R Yarnold; D F Levinson; H Singh; A S Bellack; K Kee; R L Morrison; K G Yadalam
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

8.  Alcohol use and abuse in schizophrenia. A prospective community study.

Authors:  R E Drake; F C Osher; M A Wallach
Journal:  J Nerv Ment Dis       Date:  1989-07       Impact factor: 2.254

9.  Psychotogenic drug use and neuroleptic response.

Authors:  M B Bowers; C M Mazure; J C Nelson; P I Jatlow
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

Review 10.  Pharmacological treatment of substance-abusing schizophrenic patients.

Authors:  S G Siris
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

View more
  30 in total

1.  Clozapine: a distinct, poorly understood and under-used molecule.

Authors:  Ridha Joober; Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

2.  Modafinil augments brain activation associated with reward anticipation in the nucleus accumbens.

Authors:  Takuya Funayama; Yumiko Ikeda; Amane Tateno; Hidehiko Takahashi; Yoshiro Okubo; Haruhisa Fukayama; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

3.  Responding to the challenge of co-occurring disorders: suggestions for future research.

Authors:  Stanley Sacks; Redonna Chandler; Junius Gonzales
Journal:  J Subst Abuse Treat       Date:  2007-06-15

4.  Management of persons with co-occurring severe mental illness and substance use disorder: program implications.

Authors:  Robert E Drake; Kim T Mueser; Mary F Brunette
Journal:  World Psychiatry       Date:  2007-10       Impact factor: 49.548

Review 5.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.

Authors:  Joseph T Coyle; W Brad Ruzicka; Darrick T Balu
Journal:  Am J Psychiatry       Date:  2020-12-01       Impact factor: 18.112

7.  Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan.

Authors:  Jibran Y Khokhar; David T Chau; Ree Dawson; Alan I Green
Journal:  Drug Alcohol Depend       Date:  2015-04-22       Impact factor: 4.492

8.  Role of caloric homeostasis and reward in alcohol intake in Syrian golden hamsters.

Authors:  Danielle Gulick; Alan I Green
Journal:  Physiol Behav       Date:  2010-08-03

9.  The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat.

Authors:  David T Chau; Jibran Y Khokhar; Ree Dawson; Jayme Ahmed; Haiyi Xie; Alan I Green
Journal:  Alcohol       Date:  2013-10-17       Impact factor: 2.405

10.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.